Our data are promising and, given the poor survival and current lack of existing in-time molecular disease monitoring tools for infants and children with TERT-rearranged neuroblastoma, support the blinded evaluation of our ddPCR-based assay in an accompanying prospective assessment to a clinical trial for neuroblastoma treatment. Here, TERT is linked to neuroblastoma.